Search Videos and More
News
Dana-Farber Research Publication 03.15.2024
This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
News
Dana-Farber and Gustave Roussy to Hold Third Transatlantic Exchange: Annual Scientific Conference Dedicated to Advancing Oncology Research and Practice
Dana-Farber Cancer Institute and Gustave Roussy (Grand Paris, Villejuif, France) have announced that the Third Transatlantic Exchange in Oncology Conference will address Liquid Biopsy as an Emerging Approach in Precision Cancer Medicine.
Video
Testicular Cancer Conference Highlights from ASCO GU 2024
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the testicular cancer clinical updates you need to know from ASCO GU 2024.
News
BCL2 Inhibitors: What’s the Latest Research?
BCL2 inhibitors are drugs that prompt cancer cells to die by altering the interactions among key proteins within the cells. They were clinically developed, in large part, by researchers at Dana-Farber and have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL) in adults.
News
Dana-Farber Cancer Institute Researchers Join Global Cancer Grand Challenges Team Taking on Solid Tumors in Children
Dana-Farber Cancer Institute's Scott Armstrong, MD, PhD, Benjamin Ebert, MD, PhD, Eric Fischer, PhD, Cigall Kadoch, PhD, and Kimberly Stegmaier, MD, are part of a global, interdisciplinary team of researchers, called Team PROTECT, that has been selected to receive a Cancer Grand Challenges award. The award, of up to $25 million over five years, will be used to tackle solid tumors in children.
Video
Bladder Cancer Conference Highlights from ASCO GU 2024
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the bladder cancer clinical updates you need to know from ASCO GU 2024.
Symposium
2024 ASCO GU Highlights
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the clinical updates you need to know from ASCO GU 2024.
News
Laurie H. Glimcher, MD, Selected for STAT's 2024 STATUS List
Laurie H. Glimcher, MD, president and CEO of Dana-Farber Cancer Institute, is named to STAT's 2024 STATUS List, featuring 50 influential people shaping the future of health and life sciences across biotech, medicine, health care, policy, and health tech.
News
Dana-Farber Researchers Receive AACR 2024 Scientific Achievement Awards
Christopher D.M. Fletcher, MD, Timothy R. Rebbeck, PhD, David Pellman, MD, and Gordon J. Freeman, PhD, will be recognized by the American Association for Cancer Research (AACR) with 2024 Scientific Achievement Awards.
News
Dana-Farber CEO Laurie Glimcher Has Always Been a Trail-Blazer and a Risk-Taker
Dr. Laurie Glimcher learned early on from her father, a prominent physician-researcher, that success in science was built on a basic principle: Big discoveries require big risks.
News
Antibody-Drug Conjugates: A Cancer Therapy Revolution
Dana-Farber researchers explore how a novel therapy may benefit patients
News
Immunotherapy for Cancer: What it Is, How it Works, and Where it’s Going
Immunotherapy refers to treatments that use the body’s immune system to combat diseases. Immuno-oncology focuses on efforts to use the immune system as a weapon against cancer. The immune system is a collection of organs, tissues, specialized cells, and substances that protect the body against infection and disease. While the immune system can often handle very small tumors on its own, either by destroying them or keeping them from growing, it can sometimes fail — either because a tumor grows too large, the cancer cells are too well camouflaged, or the tumor cells are able to stave off an immune system attack. A key discovery, made by Dana-Farber’s Gordon Freeman, PhD, and others, was that the immune system’s attack on cancer often falls short because many cancer cells display proteins, called immune checkpoint proteins, that bring the attack to a halt.